Regeneron pumping a further $350m into ex-Dell Irish biologics plant

By Dan Stanton

- Last updated on GMT

Regeneron's investment a further boost for Ireland's biopharma industry
Regeneron's investment a further boost for Ireland's biopharma industry

Related tags Macular degeneration Regeneron

A $350m investment will make Regeneron’s Limerick plant “the largest-scale bulk biologics production facility in Ireland,” the firm says, and add a further 200 jobs.

Biopharma firm Regeneron acquired a 400,000sq ft plant from computer manufacturer Dell in Limerick back in July 2013​ investing $300m (€265m) to convert it into a biomanufacturing site for biopharmaceuticals, including monoclonal antibodies.

Now the firm is looking to expand the site further by investing an additional $350m and adding a further 200 jobs to create by the end of 2017 a campus it says will “house the largest-scale bulk biologics production facility in Ireland.”

In March 2014​, Regeneron denied rumours it was building a fill/finish plant in Limerick to support the biologics facility, but a spokesperson from the firm today told Biopharma-Reporter this latest investment would not be for fill/finish operations.

Instead, Hala Mirza said, the $350m will be used for “continued growth and expansion of the Industrial Operations and Product Supply (IOPS) bioprocessing site,”​ supporting the firm’s ever-growing portfolio through additional capacity.

Manufacturing “will include products from our marketed and innovative pipeline of therapies,”​ such as its mAb Praluent (alirocumab), which became the first anti-PCSK9 approved in the US in July​.

Regeneron also makes the recombinant protein for (wet) age-related macular degeneration (AMD), Eylea (aflibercept), and has a number of mAb candidates in Phase II and III studies.


The news comes as a further boost for Ireland, which has become quite the hub for biomanufacturing.

Earlier this month​, ABEC opened a facility making bioprocessing technologies citing demand from an Irish biopharma industry which has seen hundreds-of-millions of dollars’ worth of investments over the past few years from the likes of Pfizer​, Merck & Co.​, and Bristol-Myers Squibbs​.

“We believe Ireland is a unique and important market for the expansion of our IOPS organization,”​ Regeneron’s Mirza told us, due to the “English language, close proximity to our European collaborators and a high-quality, talented workforce.”

Martin Shanahan, CEO of the Irish IDA (Industrial Development Agency), said: “This $350 million investment announcement from Regeneron is a huge boost for the Mid-West Region.

“Biopharma is thriving as an industry in Ireland right now, and Regeneron is a prime example of this. This new facility will provide employment to people at all levels from science, engineering and admin backgrounds.”

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers